BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast ...

Core Insights - Artios Pharma Limited has appointed three senior leaders to enhance its late-stage development capabilities and prepare for commercial readiness, including Roy W. Ware as Chief Manufacturing and Technology Officer, Caryn Barnett as Vice President of Clinical Operations, and Pablo Lee as Vice President of Medical Affairs [1][6] Group 1: Leadership Appointments - Roy W. Ware, PhD, MBA, brings over 20 years of experience in CMC strategy, manufacturing, and global supply chain leadership, previously serving at Chimerix where he oversaw FDA submissions for Tembexa® and Modeyso® [3] - Caryn Barnett has over 30 years of experience in biopharmaceuticals, having led late-phase oncology programs through registration and approval, including Cyramza® and Verzenio® [4] - Pablo Lee, MD, MBA, has more than 25 years of experience in medical practice and global medical affairs, previously involved in the launch planning of Modeyso® and has held senior roles at Eli Lilly [5] Group 2: Company Focus and Pipeline - Artios Pharma is focused on developing new classes of medicines that target DNA Damage Response (DDR) pathways, with a mission to deliver meaningful survival benefits for cancer patients [7] - The company is advancing its lead program, alnodesertib, into late-stage development and potential commercialization in the U.S., while also executing a Phase 2 study for ART6043 [1][2]

Core Insights - Tango Therapeutics, Inc. is participating in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 PM EST, with CEO Malte Peters scheduled for a fireside chat [1] - The event will be accessible via a live webcast on the company's website, with a replay available for 90 days post-presentation [2] - Tango Therapeutics is focused on discovering novel drug targets and developing precision medicine for cancer treatment, utilizing the genetic principle of synthetic lethality [3]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Suzhou Genhouse Bio Co., Ltd. 勤浩醫藥（蘇州）股份有限公司 (A joint stock company incorporated in the People's Republic of China ...

Core Viewpoint - Tango Therapeutics, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its focus on precision medicine for cancer treatment [1]. Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision medicine for cancer treatment [3]. - The company employs the genetic principle of synthetic lethality to identify and create therapies targeting critical cancer-related elements [3]. Event Details - Barbara Weber, M.D., the President and CEO of Tango Therapeutics, will deliver the corporate presentation at 9:45am PST/12:45pm EST [1]. - A live webcast of the presentation will be available on the company's website, with a replay archived for 90 days post-event [2].

Core Insights - Tango Therapeutics, Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, with Adam Crystal, M.D., Ph.D., President of Research & Development, scheduled for a fireside chat [1] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [3] - The company utilizes the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related targets [3] - More information about the company can be found on their website [3]

Lantern Pharma (NasdaqCM:LTRN) Update Summary Company Overview - **Company**: Lantern Pharma - **Drug**: LP-184 - **Focus**: Treatment of advanced solid tumors, particularly those with DNA damage repair deficiencies Key Points Industry and Drug Development - LP-184 is primarily aimed at treating advanced solid tumors, including triple-negative breast cancer (TNBC), glioblastoma (GBM), and bladder cancer, which often exhibit deficiencies in DNA damage repair pathways [2][3] - The drug has completed Phase IA trials with promising safety and tolerability data, showing significant clinical activity across various solid tumor types [3][25] - Lantern Pharma has received three orphan drug designations and two fast-track designations for LP-184, indicating strong market potential [3] Mechanism of Action - LP-184 is designed to exploit synthetic lethality, particularly in tumors with high levels of PTGR1, a gene that enhances the drug's efficacy [4][10] - The drug works by causing double-stranded breaks in DNA, which are particularly lethal to tumor cells deficient in DNA repair mechanisms [4][18] - Tumors with mutations in nucleotide excision repair and homologous recombination pathways show heightened sensitivity to LP-184 [13][14] Clinical Trial Results - The Phase IA study demonstrated a favorable safety profile, with most adverse events being grade 1 or 2 and manageable [31] - Out of 63 enrolled patients, 52 were available for tumor response assessment, with 28 patients achieving stable disease, including four with durable responses lasting over six months [34] - Notably, 87.5% of patients had PTGR1 expression levels sufficient for LP-184 activation, supporting the drug's precision medicine approach [41] Future Clinical Development - Planned Phase IB and II trials will focus on advanced monotherapy and combination therapies, particularly in TNBC and non-small cell lung cancer [26][42] - The trials will utilize a Bayesian adaptive design to expedite the process and improve patient outcomes [28] - There is a strong emphasis on biomarker-driven studies to identify patients most likely to benefit from LP-184 [46] Market Potential - The market for LP-184 is considered exceptional, with estimates suggesting that about 20% of cancers harbor DNA damage repair deficiencies, making them potential candidates for treatment [3][4] - The drug's ability to combine with other therapies, such as PARP inhibitors, positions it as a strong contender in the oncology market [54][55] Additional Insights - LP-184 has shown potential in overcoming resistance to existing therapies, including PARP inhibitors, and may also convert "cold" tumors to "hot" tumors for immunotherapy [15][54] - The drug's ability to cross the blood-brain barrier is particularly advantageous for treating brain metastases associated with TNBC [57] Conclusion - Lantern Pharma's LP-184 represents a promising advancement in the treatment of solid tumors with DNA repair deficiencies, supported by strong preclinical and early clinical data. The ongoing trials and strategic focus on precision medicine could significantly impact patient outcomes and market positioning in oncology [60]

Core Viewpoint - Repare Therapeutics has entered into a definitive arrangement agreement with XenoTherapeutics, Inc. for a proposed acquisition, with significant shareholders agreeing to support the transaction [1][2]. Group 1: Transaction Details - The transaction involves XenoTherapeutics acquiring all issued and outstanding common shares of Repare Therapeutics [1]. - Shareholders representing approximately 40% of Repare's common shares have committed to vote in favor of the transaction [2]. Group 2: Company Overview - Repare Therapeutics is a clinical-stage precision oncology company focused on developing targeted cancer therapies through a proprietary synthetic lethality approach [3]. - The company's clinical pipeline includes RP-3467, a Phase 1 Pol ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor [3]. Group 3: Proxy Statement Information - Repare intends to file a proxy statement with the SEC regarding the proposed transaction, which will contain important information for shareholders [4]. - Shareholders will be able to access the proxy statement and other relevant documents for free on the SEC's website or through the company's investor relations [5].

Core Points - Repare Therapeutics has entered into a definitive agreement to be acquired by XenoTherapeutics, with shareholders expected to receive approximately US$1.82 per share plus one contingent value right (CVR) for each common share [1][2][5] - The transaction is anticipated to close in the first quarter of 2026, subject to shareholder and court approvals [6][8] - Repare is actively pursuing additional monetization efforts for its product candidates and intellectual property [3][4] Transaction Details - Each Repare shareholder will receive a cash payment based on the company's cash balance at the time of closing, estimated at US$1.82 per share [2] - Shareholders will also receive a CVR that entitles them to additional cash payments based on future revenues from existing partnerships and potential licensing agreements [3][4] - The transaction requires approval from at least 66% of voting shareholders and a majority excluding certain interested parties [6][7] Financial Results - As of September 30, 2025, Repare reported cash and cash equivalents of $112.6 million, an increase from $109.5 million as of June 30, 2025 [17] - Revenue from collaboration agreements for the three months ended September 30, 2025, was $11.6 million, compared to nil for the same period in 2024 [17] - The company reported a net income of $3.3 million for the three months ended September 30, 2025, compared to a net loss of $34.4 million for the same period in 2024 [17][26] Board and Advisory Recommendations - The Board of Directors unanimously approved the transaction, determining it to be in the best interest of Repare and its stakeholders [5][9] - A transaction committee of independent directors recommended entering into the agreement after thorough evaluation [9] Future Implications - Following the completion of the transaction, Repare will become a privately held company, and its shares will be delisted from the Nasdaq [8] - The company plans to cease being a reporting issuer under Canadian securities laws and deregister its shares under U.S. securities laws [8]

Core Insights - Tango Therapeutics, Inc. is participating in the 2025 Jefferies Global Healthcare Conference with a presentation by CEO Barbara Weber scheduled for November 19, 2025 [1] - The event will be accessible via a live webcast on the company's website, with a replay available for 90 days post-event [2] - Tango Therapeutics focuses on discovering novel drug targets and developing precision medicine for cancer treatment, utilizing the genetic principle of synthetic lethality [3]